氨基水杨酸与安慰剂治疗具有免疫活性的HIV感染者慢性腹泻和非特异性结肠炎:一项双盲对照的先导性研究

作     者：Rodrguez-Torres M. Rodrguez-Orengo J.F. Ros-Bedoya C.F. 成虹 

作者机构：Fundación de Investigaci ón de Diego Avenida De Diego 359 Santurce 00909 Puerto Rico Dr. 

出 版 物：《世界核心医学期刊文摘（胃肠病学分册）》 (Core Journals in Gastroenterology)

年 卷 期：2006年第2卷第5期

页      面：15-16页

学科分类：100506[医学-中医内科学] 1006[医学-中西医结合] 1005[医学-中医学] 1011[医学-护理学（可授医学、理学学位）] 10[医学] 100602[医学-中西医结合临床] 

主　　题：非特异性结肠炎 安慰剂治疗 氨基水杨酸 HIV感染者 慢性腹泻 免疫活性 双盲对照 HIV阳性患者 高活性抗逆转录病毒治疗 先导性 

摘      要：Chronic diarrhea and colitis are common in patients positive for human immunodeficiency virus (HIV) under highly active antiretroviral treatment (HAART). This prospective doubleblind study explores the effect of mesalamine vs. placebo in HIV-positive patients. Thirteen HIV-infected patients with noninfectious chronic diarrhea and 250CD4+ cells/mm3 were randomized to mesalamine (2.4 g/day; n = 9) or placebo (n = 4) for 6 weeks. Colonoscopy was performed at baseline and week 6, and biopsies were obtained to calculate the Biopsy Activity Index (BAI). Diarrhea was assessed at baseline and end of treatment using the Disease Activity Index (DAI). Patients and clinicians completed Patient Global Improvement index (PGI) and Clinical Global Improvement index (CGI) at weeks 2 and 6. Comparisons at week 6 were statistically significant between mesalamine and placebo groups for BAI (P = 0.03), DAI (P = 0.007), PGI (P = 0.008), and CGI (P = 0.008). Furthermore, major improvements were documented in the mesalamine group at week 6 compared to baseline for all variables, whereas the placebo group did not have any. Mesalamine was effective for treatment of chronic diarrhea and moderate nonspecific colitis in HIV patients.